Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0560-0004 · 1 trial · 1 indication
Number of events
Number of events
Number of events
| Arm | Type | Description |
|---|---|---|
| NNC0560-0004 | EXPERIMENTAL | The study will be conducted in 3 parts. Participants will be randomized to receive NNC0560-0004 in Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD) No randomisation - only active treatment in Part C: Single dose |
| Placebo (NNC0560-0004) | PLACEBO_COMPARATOR | Participant will be randomized to receive placebo in: Part A: Single ascending dose (SAD) Part B: Multiple ascending dose (MAD) |
| Name | Type | Description |
|---|---|---|
| NNC0560-0004 | DRUG | NNC0560-0004, Oral administration (taken through the mouth) |
| Placebo (NNC0560-0004) | DRUG | Placebo matching NNC0560-0004, Oral administration (taken through the mouth) |
Key inclusion criteria: 1. Female, of non-childbearing potential, or male, both genders aged 18-55 years (both inclusive) at the time of signing informed consent. 2. Body Mass Index (BMI) between 18.5 and 29.9 kg/m\^2 (both inclusive) at screening. 3. Considered to be generally healthy based on the...
NNC0560-0004 is an investigational small molecule being studied for use in healthy volunteers and for liver diseases. It is in Phase 1 clinical development, with a completed first-in-human trial that assessed safety and blood concentrations after once-daily oral dosing in healthy adults.
NNC0560-0004 is being developed by Novo Nordisk A/S, a biopharmaceutical company listed on the stock exchange under the ticker symbol NVO. The company is conducting clinical trials to evaluate this investigational small molecule.
NNC0560-0004 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. A Phase 1 trial has been completed, and the drug remains under clinical investigation for its potential use in liver diseases.
NNC0560-0004 has one completed clinical trial, identified as NCT06133270. This was a first-in-human, Phase 1, randomized, double-blind, placebo-controlled study in the United Kingdom, enrolling 51 healthy adults to evaluate safety and blood concentrations following once-daily oral dosing.
NNC0560-0004 is the primary name for this investigational drug. No alternative names have been reported for this compound in the available clinical trial information. It is being studied under this identifier in its Phase 1 development program.
NNC0560-0004 is administered orally, once daily, as a small molecule. In the completed Phase 1 trial, healthy adult participants received the study medicine by mouth to assess its safety and how much of the drug reached the blood over time.